Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) Sees Large Increase in Short Interest

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) saw a large growth in short interest during the month of December. As of December 31st, there was short interest totalling 121,000 shares, a growth of 103.0% from the December 15th total of 59,600 shares. Approximately 0.5% of the company’s shares are short sold. Based on an average daily volume of 153,600 shares, the short-interest ratio is presently 0.8 days.

Institutional Trading of Bolt Biotherapeutics

An institutional investor recently raised its position in Bolt Biotherapeutics stock. FMR LLC grew its position in Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) by 33.2% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 115,386 shares of the company’s stock after acquiring an additional 28,773 shares during the quarter. FMR LLC owned about 0.30% of Bolt Biotherapeutics worth $75,000 as of its most recent SEC filing. Institutional investors and hedge funds own 86.70% of the company’s stock.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a “neutral” rating on shares of Bolt Biotherapeutics in a research report on Wednesday, November 13th. Five research analysts have rated the stock with a hold rating, According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $3.50.

Bolt Biotherapeutics Stock Performance

Shares of BOLT stock traded down $0.00 during mid-day trading on Tuesday, reaching $0.53. The stock had a trading volume of 7,945 shares, compared to its average volume of 145,766. The business’s fifty day moving average is $0.57 and its 200-day moving average is $0.64. The company has a current ratio of 3.16, a quick ratio of 3.16 and a debt-to-equity ratio of 0.21. The firm has a market cap of $20.13 million, a price-to-earnings ratio of -0.31 and a beta of 0.96. Bolt Biotherapeutics has a 1-year low of $0.48 and a 1-year high of $1.56.

Bolt Biotherapeutics (NASDAQ:BOLT) last posted its earnings results on Tuesday, November 12th. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.36) by ($0.04). The company had revenue of $1.14 million for the quarter, compared to analyst estimates of $1.02 million. Bolt Biotherapeutics had a negative return on equity of 69.46% and a negative net margin of 665.56%. On average, research analysts forecast that Bolt Biotherapeutics will post -1.61 earnings per share for the current year.

Bolt Biotherapeutics Company Profile

Bolt Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company’s lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.